WO2008059625A1 - Utilization of the function of rare sugar as promoter for the migration of glucokinase from nucleus to cytoplasm - Google Patents
Utilization of the function of rare sugar as promoter for the migration of glucokinase from nucleus to cytoplasm Download PDFInfo
- Publication number
- WO2008059625A1 WO2008059625A1 PCT/JP2007/056445 JP2007056445W WO2008059625A1 WO 2008059625 A1 WO2008059625 A1 WO 2008059625A1 JP 2007056445 W JP2007056445 W JP 2007056445W WO 2008059625 A1 WO2008059625 A1 WO 2008059625A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- darcokinase
- psicose
- food
- activity
- glucose
- Prior art date
Links
- 210000000805 cytoplasm Anatomy 0.000 title claims abstract description 103
- 235000000346 sugar Nutrition 0.000 title abstract description 27
- 102000030595 Glucokinase Human genes 0.000 title abstract description 8
- 108010021582 Glucokinase Proteins 0.000 title abstract description 8
- 230000005012 migration Effects 0.000 title abstract description 8
- 238000013508 migration Methods 0.000 title abstract description 8
- 230000000694 effects Effects 0.000 claims abstract description 87
- BJHIKXHVCXFQLS-PUFIMZNGSA-N D-psicose Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)C(=O)CO BJHIKXHVCXFQLS-PUFIMZNGSA-N 0.000 claims abstract description 82
- 239000000203 mixture Substances 0.000 claims abstract description 52
- 235000013305 food Nutrition 0.000 claims abstract description 51
- LKDRXBCSQODPBY-OEXCPVAWSA-N D-tagatose Chemical compound OCC1(O)OC[C@@H](O)[C@H](O)[C@@H]1O LKDRXBCSQODPBY-OEXCPVAWSA-N 0.000 claims abstract description 45
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims abstract description 34
- 239000004480 active ingredient Substances 0.000 claims abstract description 22
- 208000001145 Metabolic Syndrome Diseases 0.000 claims abstract description 20
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims abstract description 20
- 208000002705 Glucose Intolerance Diseases 0.000 claims abstract description 19
- 201000009104 prediabetes syndrome Diseases 0.000 claims abstract description 19
- 208000008589 Obesity Diseases 0.000 claims abstract description 17
- 239000003814 drug Substances 0.000 claims abstract description 17
- 235000020824 obesity Nutrition 0.000 claims abstract description 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 14
- 235000013373 food additive Nutrition 0.000 claims abstract description 11
- 239000002778 food additive Substances 0.000 claims abstract description 11
- 239000000463 material Substances 0.000 claims abstract description 11
- 235000013402 health food Nutrition 0.000 claims abstract description 10
- 230000036541 health Effects 0.000 claims abstract description 9
- 239000003937 drug carrier Substances 0.000 claims abstract description 6
- 238000012546 transfer Methods 0.000 claims description 32
- 230000001575 pathological effect Effects 0.000 claims description 17
- 230000002265 prevention Effects 0.000 claims description 17
- 230000001737 promoting effect Effects 0.000 claims description 15
- 201000010099 disease Diseases 0.000 claims description 12
- 208000031226 Hyperlipidaemia Diseases 0.000 claims description 11
- 239000008187 granular material Substances 0.000 claims description 10
- 239000002775 capsule Substances 0.000 claims description 9
- 239000003795 chemical substances by application Substances 0.000 claims description 9
- 235000013376 functional food Nutrition 0.000 claims description 6
- 239000000843 powder Substances 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 5
- 239000013589 supplement Substances 0.000 claims description 3
- 235000015872 dietary supplement Nutrition 0.000 claims description 2
- 230000008506 pathogenesis Effects 0.000 claims 2
- 150000008163 sugars Chemical class 0.000 abstract description 14
- 239000012190 activator Substances 0.000 abstract description 5
- 206010022489 Insulin Resistance Diseases 0.000 abstract description 4
- 229940079593 drug Drugs 0.000 abstract description 3
- 229940124828 glucokinase activator Drugs 0.000 abstract 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 126
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 126
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 66
- 239000008103 glucose Substances 0.000 description 66
- RFSUNEUAIZKAJO-VRPWFDPXSA-N D-Fructose Natural products OC[C@H]1OC(O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-VRPWFDPXSA-N 0.000 description 64
- 210000004940 nucleus Anatomy 0.000 description 64
- 210000004369 blood Anatomy 0.000 description 39
- 239000008280 blood Substances 0.000 description 39
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 39
- 210000004185 liver Anatomy 0.000 description 31
- 238000000034 method Methods 0.000 description 31
- 210000003494 hepatocyte Anatomy 0.000 description 30
- 230000005945 translocation Effects 0.000 description 25
- 241000700159 Rattus Species 0.000 description 24
- 150000001875 compounds Chemical class 0.000 description 23
- 230000001086 cytosolic effect Effects 0.000 description 22
- -1 D-manntol Chemical compound 0.000 description 21
- 238000009826 distribution Methods 0.000 description 20
- 102000004877 Insulin Human genes 0.000 description 19
- 108090001061 Insulin Proteins 0.000 description 19
- 229940125396 insulin Drugs 0.000 description 19
- 108090000623 proteins and genes Proteins 0.000 description 19
- 230000007704 transition Effects 0.000 description 19
- 102000004169 proteins and genes Human genes 0.000 description 18
- 210000003462 vein Anatomy 0.000 description 17
- 238000002474 experimental method Methods 0.000 description 16
- 230000002440 hepatic effect Effects 0.000 description 16
- 210000003240 portal vein Anatomy 0.000 description 16
- 238000004519 manufacturing process Methods 0.000 description 15
- 210000004027 cell Anatomy 0.000 description 13
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 12
- 239000008194 pharmaceutical composition Substances 0.000 description 12
- 241001465754 Metazoa Species 0.000 description 11
- 230000003247 decreasing effect Effects 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 10
- 102000051325 Glucagon Human genes 0.000 description 9
- 108060003199 Glucagon Proteins 0.000 description 9
- BJHIKXHVCXFQLS-ZXEDONINSA-N L-psicose Chemical compound OC[C@H](O)[C@H](O)[C@H](O)C(=O)CO BJHIKXHVCXFQLS-ZXEDONINSA-N 0.000 description 9
- 229930006000 Sucrose Natural products 0.000 description 9
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 9
- 229960004666 glucagon Drugs 0.000 description 9
- 230000004153 glucose metabolism Effects 0.000 description 9
- 230000003914 insulin secretion Effects 0.000 description 9
- 239000005720 sucrose Substances 0.000 description 9
- 229960004793 sucrose Drugs 0.000 description 9
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 8
- 235000003599 food sweetener Nutrition 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 239000003765 sweetening agent Substances 0.000 description 8
- 150000008165 D-ketoses Chemical class 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- 102000005548 Hexokinase Human genes 0.000 description 7
- 108700040460 Hexokinases Proteins 0.000 description 7
- 208000007976 Ketosis Diseases 0.000 description 7
- 239000002585 base Substances 0.000 description 7
- 238000000576 coating method Methods 0.000 description 7
- 102000034356 gene-regulatory proteins Human genes 0.000 description 7
- 108091006104 gene-regulatory proteins Proteins 0.000 description 7
- 210000003016 hypothalamus Anatomy 0.000 description 7
- 230000003834 intracellular effect Effects 0.000 description 7
- 150000002584 ketoses Chemical class 0.000 description 7
- 230000007246 mechanism Effects 0.000 description 7
- 230000001105 regulatory effect Effects 0.000 description 7
- WQZGKKKJIJFFOK-SVZMEOIVSA-N (+)-Galactose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-SVZMEOIVSA-N 0.000 description 6
- NDVRKEKNSBMTAX-BTVCFUMJSA-N (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal;phosphoric acid Chemical compound OP(O)(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O NDVRKEKNSBMTAX-BTVCFUMJSA-N 0.000 description 6
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 6
- 241000124008 Mammalia Species 0.000 description 6
- 239000003472 antidiabetic agent Substances 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- 239000011248 coating agent Substances 0.000 description 6
- 239000003086 colorant Substances 0.000 description 6
- 206010012601 diabetes mellitus Diseases 0.000 description 6
- 238000010586 diagram Methods 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 239000004310 lactic acid Substances 0.000 description 6
- 235000014655 lactic acid Nutrition 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 230000003393 splenic effect Effects 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 5
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 5
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 5
- 239000003524 antilipemic agent Substances 0.000 description 5
- 235000013361 beverage Nutrition 0.000 description 5
- 239000011230 binding agent Substances 0.000 description 5
- 230000033228 biological regulation Effects 0.000 description 5
- 239000001768 carboxy methyl cellulose Substances 0.000 description 5
- 235000010980 cellulose Nutrition 0.000 description 5
- 229920002678 cellulose Polymers 0.000 description 5
- 239000001913 cellulose Substances 0.000 description 5
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 239000007884 disintegrant Substances 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- 229940088597 hormone Drugs 0.000 description 5
- 239000005556 hormone Substances 0.000 description 5
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 5
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 5
- 239000000314 lubricant Substances 0.000 description 5
- 235000012054 meals Nutrition 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 210000000952 spleen Anatomy 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- 229940124597 therapeutic agent Drugs 0.000 description 5
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 4
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 4
- 239000005715 Fructose Substances 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 229920002527 Glycogen Polymers 0.000 description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- 229930040373 Paraformaldehyde Natural products 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 239000000883 anti-obesity agent Substances 0.000 description 4
- 229940125708 antidiabetic agent Drugs 0.000 description 4
- 239000002220 antihypertensive agent Substances 0.000 description 4
- 239000003963 antioxidant agent Substances 0.000 description 4
- 235000006708 antioxidants Nutrition 0.000 description 4
- 210000003719 b-lymphocyte Anatomy 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 239000000496 cardiotonic agent Substances 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 239000003995 emulsifying agent Substances 0.000 description 4
- 239000007888 film coating Substances 0.000 description 4
- 238000009501 film coating Methods 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 4
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 4
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 4
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 229960001375 lactose Drugs 0.000 description 4
- 210000005229 liver cell Anatomy 0.000 description 4
- 238000011068 loading method Methods 0.000 description 4
- 235000010355 mannitol Nutrition 0.000 description 4
- 230000004060 metabolic process Effects 0.000 description 4
- 229920002866 paraformaldehyde Polymers 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 229940032147 starch Drugs 0.000 description 4
- 239000002562 thickening agent Substances 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 229940088594 vitamin Drugs 0.000 description 4
- 229930003231 vitamin Natural products 0.000 description 4
- 235000013343 vitamin Nutrition 0.000 description 4
- 239000011782 vitamin Substances 0.000 description 4
- 244000215068 Acacia senegal Species 0.000 description 3
- 206010002091 Anaesthesia Diseases 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- NBSCHQHZLSJFNQ-GASJEMHNSA-N D-Glucose 6-phosphate Chemical compound OC1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@H]1O NBSCHQHZLSJFNQ-GASJEMHNSA-N 0.000 description 3
- LKDRXBCSQODPBY-JDJSBBGDSA-N D-allulose Chemical compound OCC1(O)OC[C@@H](O)[C@@H](O)[C@H]1O LKDRXBCSQODPBY-JDJSBBGDSA-N 0.000 description 3
- 229920001353 Dextrin Polymers 0.000 description 3
- 239000004375 Dextrin Substances 0.000 description 3
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- VFRROHXSMXFLSN-UHFFFAOYSA-N Glc6P Natural products OP(=O)(O)OCC(O)C(O)C(O)C(O)C=O VFRROHXSMXFLSN-UHFFFAOYSA-N 0.000 description 3
- 229920000084 Gum arabic Polymers 0.000 description 3
- LKDRXBCSQODPBY-AMVSKUEXSA-N L-(-)-Sorbose Chemical compound OCC1(O)OC[C@H](O)[C@@H](O)[C@@H]1O LKDRXBCSQODPBY-AMVSKUEXSA-N 0.000 description 3
- 150000008164 L-ketoses Chemical class 0.000 description 3
- 229920000881 Modified starch Polymers 0.000 description 3
- 108091000080 Phosphotransferase Proteins 0.000 description 3
- 239000004373 Pullulan Substances 0.000 description 3
- 229920001218 Pullulan Polymers 0.000 description 3
- 235000010489 acacia gum Nutrition 0.000 description 3
- 239000000205 acacia gum Substances 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 230000037005 anaesthesia Effects 0.000 description 3
- 229940030600 antihypertensive agent Drugs 0.000 description 3
- 229940125710 antiobesity agent Drugs 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- RHKKZBWRNHGJEZ-ARQDHWQXSA-N beta-D-fructofuranose 1-phosphate Chemical compound OC[C@H]1O[C@](O)(COP(O)(O)=O)[C@@H](O)[C@@H]1O RHKKZBWRNHGJEZ-ARQDHWQXSA-N 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 210000003855 cell nucleus Anatomy 0.000 description 3
- 235000019425 dextrin Nutrition 0.000 description 3
- 239000003651 drinking water Substances 0.000 description 3
- 235000020188 drinking water Nutrition 0.000 description 3
- 235000013355 food flavoring agent Nutrition 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 230000004110 gluconeogenesis Effects 0.000 description 3
- 229940096919 glycogen Drugs 0.000 description 3
- 150000002402 hexoses Chemical class 0.000 description 3
- 230000002218 hypoglycaemic effect Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 229940117841 methacrylic acid copolymer Drugs 0.000 description 3
- 229920003145 methacrylic acid copolymer Polymers 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 150000002772 monosaccharides Chemical class 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 102000020233 phosphotransferase Human genes 0.000 description 3
- 239000000049 pigment Substances 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 235000019423 pullulan Nutrition 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 3
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 3
- 150000005846 sugar alcohols Chemical class 0.000 description 3
- 239000000375 suspending agent Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 235000012222 talc Nutrition 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 239000001993 wax Substances 0.000 description 3
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 2
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- LKDRXBCSQODPBY-IANNHFEVSA-N D-sorbose Chemical compound OCC1(O)OC[C@@H](O)[C@H](O)[C@H]1O LKDRXBCSQODPBY-IANNHFEVSA-N 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- 206010018429 Glucose tolerance impaired Diseases 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 108010044467 Isoenzymes Proteins 0.000 description 2
- LKDRXBCSQODPBY-NSHGFSBMSA-N L-fructose Chemical compound OCC1(O)OC[C@H](O)[C@H](O)[C@H]1O LKDRXBCSQODPBY-NSHGFSBMSA-N 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Chemical compound CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 description 2
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- VYGQUTWHTHXGQB-FFHKNEKCSA-N Retinol Palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C VYGQUTWHTHXGQB-FFHKNEKCSA-N 0.000 description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- 244000299461 Theobroma cacao Species 0.000 description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
- YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000006172 buffering agent Substances 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 229940105329 carboxymethylcellulose Drugs 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 235000013351 cheese Nutrition 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000011260 co-administration Methods 0.000 description 2
- 210000004748 cultured cell Anatomy 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 238000004042 decolorization Methods 0.000 description 2
- 230000003544 deproteinization Effects 0.000 description 2
- 238000011033 desalting Methods 0.000 description 2
- 235000013325 dietary fiber Nutrition 0.000 description 2
- 230000035622 drinking Effects 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000002073 fluorescence micrograph Methods 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 238000005194 fractionation Methods 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 230000014101 glucose homeostasis Effects 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 230000034659 glycolysis Effects 0.000 description 2
- 235000009200 high fat diet Nutrition 0.000 description 2
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 210000005061 intracellular organelle Anatomy 0.000 description 2
- 239000003456 ion exchange resin Substances 0.000 description 2
- 229920003303 ion-exchange polymer Polymers 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 229960003511 macrogol Drugs 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 230000000873 masking effect Effects 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 239000003094 microcapsule Substances 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 210000003470 mitochondria Anatomy 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 230000000291 postprandial effect Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 235000005713 safflower oil Nutrition 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 239000007901 soft capsule Substances 0.000 description 2
- 229960002920 sorbitol Drugs 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 229940083466 soybean lecithin Drugs 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 238000009495 sugar coating Methods 0.000 description 2
- 230000009469 supplementation Effects 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- KZJWDPNRJALLNS-VPUBHVLGSA-N (-)-beta-Sitosterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]([C@H](CC[C@@H](C(C)C)CC)C)CC4)CC3)CC=2)CC1 KZJWDPNRJALLNS-VPUBHVLGSA-N 0.000 description 1
- JQWAHKMIYCERGA-UHFFFAOYSA-N (2-nonanoyloxy-3-octadeca-9,12-dienoyloxypropoxy)-[2-(trimethylazaniumyl)ethyl]phosphinate Chemical compound CCCCCCCCC(=O)OC(COP([O-])(=O)CC[N+](C)(C)C)COC(=O)CCCCCCCC=CCC=CCCCCC JQWAHKMIYCERGA-UHFFFAOYSA-N 0.000 description 1
- CSVWWLUMXNHWSU-UHFFFAOYSA-N (22E)-(24xi)-24-ethyl-5alpha-cholest-22-en-3beta-ol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(CC)C(C)C)C1(C)CC2 CSVWWLUMXNHWSU-UHFFFAOYSA-N 0.000 description 1
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 description 1
- PXBFMLJZNCDSMP-UHFFFAOYSA-N 2-Aminobenzamide Chemical class NC(=O)C1=CC=CC=C1N PXBFMLJZNCDSMP-UHFFFAOYSA-N 0.000 description 1
- YGZFYDFBHIDIBH-UHFFFAOYSA-N 2-[bis(2-hydroxyethyl)amino]icosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCC(CO)N(CCO)CCO YGZFYDFBHIDIBH-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-GASJEMHNSA-N 2-amino-2-deoxy-D-galactopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O MSWZFWKMSRAUBD-GASJEMHNSA-N 0.000 description 1
- KLEXDBGYSOIREE-UHFFFAOYSA-N 24xi-n-propylcholesterol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CCC)C(C)C)C1(C)CC2 KLEXDBGYSOIREE-UHFFFAOYSA-N 0.000 description 1
- AEDQNOLIADXSBB-UHFFFAOYSA-N 3-(dodecylazaniumyl)propanoate Chemical compound CCCCCCCCCCCCNCCC(O)=O AEDQNOLIADXSBB-UHFFFAOYSA-N 0.000 description 1
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 description 1
- RSWGJHLUYNHPMX-UHFFFAOYSA-N Abietic-Saeure Natural products C12CCC(C(C)C)=CC2=CCC2C1(C)CCCC2(C)C(O)=O RSWGJHLUYNHPMX-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 229910002012 Aerosil® Inorganic materials 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 240000002791 Brassica napus Species 0.000 description 1
- 235000004977 Brassica sinapistrum Nutrition 0.000 description 1
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 1
- SGNBVLSWZMBQTH-FGAXOLDCSA-N Campesterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]([C@H](CC[C@H](C(C)C)C)C)CC4)CC3)CC=2)CC1 SGNBVLSWZMBQTH-FGAXOLDCSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 229920001268 Cholestyramine Polymers 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- LPZCCMIISIBREI-MTFRKTCUSA-N Citrostadienol Natural products CC=C(CC[C@@H](C)[C@H]1CC[C@H]2C3=CC[C@H]4[C@H](C)[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C LPZCCMIISIBREI-MTFRKTCUSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- 102000010831 Cytoskeletal Proteins Human genes 0.000 description 1
- 108010037414 Cytoskeletal Proteins Proteins 0.000 description 1
- GSXOAOHZAIYLCY-UHFFFAOYSA-N D-F6P Natural products OCC(=O)C(O)C(O)C(O)COP(O)(O)=O GSXOAOHZAIYLCY-UHFFFAOYSA-N 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 1
- AEMOLEFTQBMNLQ-VANFPWTGSA-N D-mannopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H]1O AEMOLEFTQBMNLQ-VANFPWTGSA-N 0.000 description 1
- 150000000837 D-psicose derivatives Chemical class 0.000 description 1
- ARVGMISWLZPBCH-UHFFFAOYSA-N Dehydro-beta-sitosterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)CCC(CC)C(C)C)CCC33)C)C3=CC=C21 ARVGMISWLZPBCH-UHFFFAOYSA-N 0.000 description 1
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 description 1
- 102100021238 Dynamin-2 Human genes 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 229920003148 Eudragit® E polymer Polymers 0.000 description 1
- 229920003138 Eudragit® L 30 D-55 Polymers 0.000 description 1
- 229920003136 Eudragit® L polymer Polymers 0.000 description 1
- 229920003137 Eudragit® S polymer Polymers 0.000 description 1
- YXWOAJXNVLXPMU-ZXXMMSQZSA-N Fructose 2,6-diphosphate Chemical compound OP(=O)(O)O[C@]1(CO)O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O YXWOAJXNVLXPMU-ZXXMMSQZSA-N 0.000 description 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical class C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 description 1
- 241000589236 Gluconobacter Species 0.000 description 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 1
- BIVBRWYINDPWKA-VLQRKCJKSA-L Glycyrrhizinate dipotassium Chemical compound [K+].[K+].O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C([O-])=O)[C@@H]1O[C@H](C([O-])=O)[C@@H](O)[C@H](O)[C@H]1O BIVBRWYINDPWKA-VLQRKCJKSA-L 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- BTEISVKTSQLKST-UHFFFAOYSA-N Haliclonasterol Natural products CC(C=CC(C)C(C)(C)C)C1CCC2C3=CC=C4CC(O)CCC4(C)C3CCC12C BTEISVKTSQLKST-UHFFFAOYSA-N 0.000 description 1
- 101000817607 Homo sapiens Dynamin-2 Proteins 0.000 description 1
- 101000684208 Homo sapiens Prolyl endopeptidase FAP Proteins 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 229940122199 Insulin secretagogue Drugs 0.000 description 1
- 229940122355 Insulin sensitizer Drugs 0.000 description 1
- 102100023418 Ketohexokinase Human genes 0.000 description 1
- 108010062852 Ketohexokinase Proteins 0.000 description 1
- 108010018080 L-arabinose isomerase Proteins 0.000 description 1
- 150000001094 L-psicoses Chemical class 0.000 description 1
- 229920000057 Mannan Polymers 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 description 1
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 208000001280 Prediabetic State Diseases 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- KHPCPRHQVVSZAH-HUOMCSJISA-N Rosin Natural products O(C/C=C/c1ccccc1)[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 KHPCPRHQVVSZAH-HUOMCSJISA-N 0.000 description 1
- WINXNKPZLFISPD-UHFFFAOYSA-M Saccharin sodium Chemical compound [Na+].C1=CC=C2C(=O)[N-]S(=O)(=O)C2=C1 WINXNKPZLFISPD-UHFFFAOYSA-M 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- ABBQHOQBGMUPJH-UHFFFAOYSA-M Sodium salicylate Chemical compound [Na+].OC1=CC=CC=C1C([O-])=O ABBQHOQBGMUPJH-UHFFFAOYSA-M 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- HZYXFRGVBOPPNZ-UHFFFAOYSA-N UNPD88870 Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)=CCC(CC)C(C)C)C1(C)CC2 HZYXFRGVBOPPNZ-UHFFFAOYSA-N 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- 239000005862 Whey Substances 0.000 description 1
- 102000007544 Whey Proteins Human genes 0.000 description 1
- 108010046377 Whey Proteins Proteins 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 150000001253 acrylic acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000005273 aeration Methods 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 125000003172 aldehyde group Chemical group 0.000 description 1
- IAJILQKETJEXLJ-RSJOWCBRSA-N aldehydo-D-galacturonic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-RSJOWCBRSA-N 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 230000003281 allosteric effect Effects 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- AEMOLEFTQBMNLQ-WAXACMCWSA-N alpha-D-glucuronic acid Chemical compound O[C@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-WAXACMCWSA-N 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 125000004103 aminoalkyl group Chemical group 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 230000001458 anti-acid effect Effects 0.000 description 1
- 229940127003 anti-diabetic drug Drugs 0.000 description 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 230000003579 anti-obesity Effects 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 210000003403 autonomic nervous system Anatomy 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
- 229960001950 benzethonium chloride Drugs 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- MJVXAPPOFPTTCA-UHFFFAOYSA-N beta-Sistosterol Natural products CCC(CCC(C)C1CCC2C3CC=C4C(C)C(O)CCC4(C)C3CCC12C)C(C)C MJVXAPPOFPTTCA-UHFFFAOYSA-N 0.000 description 1
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- NEDGUIRITORSKL-UHFFFAOYSA-N butyl 2-methylprop-2-enoate;2-(dimethylamino)ethyl 2-methylprop-2-enoate;methyl 2-methylprop-2-enoate Chemical compound COC(=O)C(C)=C.CCCCOC(=O)C(C)=C.CN(C)CCOC(=O)C(C)=C NEDGUIRITORSKL-UHFFFAOYSA-N 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- 229960002079 calcium pantothenate Drugs 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000000431 campesterol Nutrition 0.000 description 1
- SGNBVLSWZMBQTH-PODYLUTMSA-N campesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](C)C(C)C)[C@@]1(C)CC2 SGNBVLSWZMBQTH-PODYLUTMSA-N 0.000 description 1
- 230000025938 carbohydrate utilization Effects 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 229940084030 carboxymethylcellulose calcium Drugs 0.000 description 1
- 230000003177 cardiotonic effect Effects 0.000 description 1
- 239000004203 carnauba wax Substances 0.000 description 1
- 235000013869 carnauba wax Nutrition 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 150000001768 cations Chemical group 0.000 description 1
- 239000003518 caustics Substances 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 229930002875 chlorophyll Natural products 0.000 description 1
- 235000019804 chlorophyll Nutrition 0.000 description 1
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- QWJSAWXRUVVRLH-UHFFFAOYSA-M choline bitartrate Chemical compound C[N+](C)(C)CCO.OC(=O)C(O)C(O)C([O-])=O QWJSAWXRUVVRLH-UHFFFAOYSA-M 0.000 description 1
- 229960004874 choline bitartrate Drugs 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 229940101029 dipotassium glycyrrhizinate Drugs 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- GDCRSXZBSIRSFR-UHFFFAOYSA-N ethyl prop-2-enoate;2-methylprop-2-enoic acid Chemical compound CC(=C)C(O)=O.CCOC(=O)C=C GDCRSXZBSIRSFR-UHFFFAOYSA-N 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 229940125753 fibrate Drugs 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 230000001890 gluconeogenic effect Effects 0.000 description 1
- 229950006191 gluconic acid Drugs 0.000 description 1
- 230000009229 glucose formation Effects 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 230000004121 glycogenesis Effects 0.000 description 1
- 230000002414 glycolytic effect Effects 0.000 description 1
- 150000002337 glycosamines Chemical class 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 229920000591 gum Polymers 0.000 description 1
- 125000001072 heteroaryl group Chemical group 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 1
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 1
- 229920000639 hydroxypropylmethylcellulose acetate succinate Polymers 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 238000006317 isomerization reaction Methods 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- GSXOAOHZAIYLCY-HSUXUTPPSA-N keto-D-fructose 6-phosphate Chemical compound OCC(=O)[C@@H](O)[C@H](O)[C@H](O)COP(O)(O)=O GSXOAOHZAIYLCY-HSUXUTPPSA-N 0.000 description 1
- BJHIKXHVCXFQLS-PQLUHFTBSA-N keto-D-tagatose Chemical compound OC[C@@H](O)[C@H](O)[C@H](O)C(=O)CO BJHIKXHVCXFQLS-PQLUHFTBSA-N 0.000 description 1
- BJHIKXHVCXFQLS-LFRDXLMFSA-N keto-L-tagatose Chemical compound OC[C@H](O)[C@@H](O)[C@@H](O)C(=O)CO BJHIKXHVCXFQLS-LFRDXLMFSA-N 0.000 description 1
- 125000000468 ketone group Chemical group 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
- HZZOEADXZLYIHG-UHFFFAOYSA-N magnesiomagnesium Chemical compound [Mg][Mg] HZZOEADXZLYIHG-UHFFFAOYSA-N 0.000 description 1
- 229940037627 magnesium lauryl sulfate Drugs 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- HBNDBUATLJAUQM-UHFFFAOYSA-L magnesium;dodecyl sulfate Chemical compound [Mg+2].CCCCCCCCCCCCOS([O-])(=O)=O.CCCCCCCCCCCCOS([O-])(=O)=O HBNDBUATLJAUQM-UHFFFAOYSA-L 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- WVJKHCGMRZGIJH-UHFFFAOYSA-N methanetriamine Chemical compound NC(N)N WVJKHCGMRZGIJH-UHFFFAOYSA-N 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000013379 molasses Nutrition 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 229920001206 natural gum Polymers 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000022001 negative regulation of insulin secretion Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 230000005937 nuclear translocation Effects 0.000 description 1
- 229940060184 oil ingredients Drugs 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000002638 palliative care Methods 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 210000004738 parenchymal cell Anatomy 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 229940021222 peritoneal dialysis isotonic solution Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- IBBMAWULFFBRKK-UHFFFAOYSA-N picolinamide Chemical class NC(=O)C1=CC=CC=N1 IBBMAWULFFBRKK-UHFFFAOYSA-N 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229940068965 polysorbates Drugs 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 229940088417 precipitated calcium carbonate Drugs 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 150000003192 psicose derivatives Chemical class 0.000 description 1
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 1
- 229960004172 pyridoxine hydrochloride Drugs 0.000 description 1
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 description 1
- 239000011764 pyridoxine hydrochloride Substances 0.000 description 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 235000019172 retinyl palmitate Nutrition 0.000 description 1
- 229940108325 retinyl palmitate Drugs 0.000 description 1
- 239000011769 retinyl palmitate Substances 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 235000019192 riboflavin Nutrition 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 238000005185 salting out Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000021309 simple sugar Nutrition 0.000 description 1
- 229960002930 sirolimus Drugs 0.000 description 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
- 235000015500 sitosterol Nutrition 0.000 description 1
- 229950005143 sitosterol Drugs 0.000 description 1
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 1
- NLQLSVXGSXCXFE-UHFFFAOYSA-N sitosterol Natural products CC=C(/CCC(C)C1CC2C3=CCC4C(C)C(O)CCC4(C)C3CCC2(C)C1)C(C)C NLQLSVXGSXCXFE-UHFFFAOYSA-N 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 description 1
- 235000010378 sodium ascorbate Nutrition 0.000 description 1
- 229960005055 sodium ascorbate Drugs 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 229960004025 sodium salicylate Drugs 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 239000004059 squalene synthase inhibitor Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 235000016831 stigmasterol Nutrition 0.000 description 1
- 229940032091 stigmasterol Drugs 0.000 description 1
- HCXVJBMSMIARIN-PHZDYDNGSA-N stigmasterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)/C=C/[C@@H](CC)C(C)C)[C@@]1(C)CC2 HCXVJBMSMIARIN-PHZDYDNGSA-N 0.000 description 1
- BFDNMXAIBMJLBB-UHFFFAOYSA-N stigmasterol Natural products CCC(C=CC(C)C1CCCC2C3CC=C4CC(O)CCC4(C)C3CCC12C)C(C)C BFDNMXAIBMJLBB-UHFFFAOYSA-N 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- KHPCPRHQVVSZAH-UHFFFAOYSA-N trans-cinnamyl beta-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OCC=CC1=CC=CC=C1 KHPCPRHQVVSZAH-UHFFFAOYSA-N 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- UGZADUVQMDAIAO-UHFFFAOYSA-L zinc hydroxide Chemical compound [OH-].[OH-].[Zn+2] UGZADUVQMDAIAO-UHFFFAOYSA-L 0.000 description 1
- 229940007718 zinc hydroxide Drugs 0.000 description 1
- 229910021511 zinc hydroxide Inorganic materials 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/121—Ketones acyclic
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H3/00—Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
- C07H3/02—Monosaccharides
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Definitions
- the present invention relates to a composition for preventing or treating the onset of pathological conditions related to darcokinase activity, comprising rare sugar D-psicose and / or D-tagatose as active ingredients.
- Darcokinase (EC 2.7.1.1) is one of four hexokinases found in mammals. Hexokinase catalyzes the first step in the metabolism of D-glucose, namely the conversion of glucose to D-glucose 6-phosphate. Darcokinase has a limited cell distribution and is found mainly in spleen ⁇ cells, liver parenchymal cells, hypothalamus, and intestinal tract. The liver is an important organ for maintaining blood glucose homeostasis.
- Darcokinase one of the rate-determining enzymes of glycolysis in liver glucose metabolism, binds to darcokinase regulatory protein in the cell nucleus during fasting and exists in an inactive form, increasing the extracellular D-glucose concentration. In the presence of low concentrations of D-fructose, it dissociates from the protein that regulates the activity of dalcokinase and moves to the nuclear cytoplasm, promoting D-glucose metabolism. The translocation of dalcokinase between the nucleus I and the cytoplasm is regulated by hormones. Insulin transfers darcokinase to the nuclear cytoplasm and glucagon to the cytoplasmic nucleus.
- D-glucose production is due to the release of D-darcose from stored glycogen or gluconeogenesis (de novo intracellular synthesis of D-glucose from gluconeogenic precursors, D-glucose-6-phosphatase Induced by an enzyme-mediated process).
- type 2 diabetes decreased glucose utilization and increased gluconeogenesis in the liver are observed.
- Liver D-glucose production cannot be adequately controlled and / or increased, and in some cases fasting D-glucose production may more than double.
- Some patients with impaired glucose tolerance may have hyperglycemia after meals even though their fasting blood glucose levels are normal.
- Insufficient insulin secretion Increase in postprandial blood glucose level due to abnormalities in hepatic glucose utilization and / or sugar production after meals due to insulin resistance and decreased sugar utilization in muscle and adipose tissue.
- dalcokinase is also present in the hypothalamus and functions as a glucose sensor. Even in the hypothalamus, the presence of dalcokinase activity-regulating protein, and the presence of dalcokinase in both bound and free forms, the nucleokines of dalcokinase by rare sugars in the hypothalamus contribute to the cytoplasm. Increased darcokinase activity due to migration, or increased darcokinase activity due to increased free dalcokinase from bound dalcokinase, the change is transmitted to peripheral tissues via the nervous system, and glucose utilization is increased in peripheral tissues It will help to prevent and treat glucose tolerance, diabetes, obesity, and metabolic syndrome.
- darcokinase is present in the cytoplasm and part of the insulin secretory condyles in the nucleus, so that glucose tolerance is also increased in spleen j8 cells through an increase in insulin secretion due to an increase in dalcokinase activity by rare sugars. It can be expected to help prevent and treat abnormalities and diabetes.
- Darcokinase activators increase the rate of glucose metabolism in cells and hepatocytes, coupled with increased insulin secretion. Such drugs would be useful for the treatment of type 2 diabetes.
- Patent Document 1 genes encoding dalcokinase, D_darcosose, cAMP, retinoic acid, etc.
- Patent Document 2 substituted furacetamide
- Patent Document 3 heteroaryl rubamoylbenzene derivative
- aminobenzamide derivatives Patent Document 4
- Patent Document 5 pyridine 2 carboxamide derivatives
- Patent Document 1 Japanese Unexamined Patent Application Publication No. 2004-018403
- Patent Document 2 Reissue 2003-532718
- Patent Document 3 Reissue 2004-076420
- Patent Document 4 Reissue Table 2003-080585
- Patent Document 5 Reissue 2004- 080001
- the present inventors investigated the signal transduction system of the nuclear I-cytoplasmic transition of hepatic darcokinase by insulin and glucagon for the purpose of developing a therapeutic agent for diabetes by promoting the transition of liver darcokinase from the nucleus to the cytoplasm.
- the present invention provides a treatment (prevention or treatment) for a medical condition associated with darcokinase activity by simply eating, drinking, or orally administering the food additive, food material, food or drink, health food or drink, pharmaceutical, or feed. It is intended to provide technology for the use of rare sugars D-psicose and / or D-tagatose.
- the gist of the present invention is the promoter for the transition from the nucleus to the cytoplasm of dalcokinase described in (1) below.
- a promoter for the transfer of darcokinase from the nucleus to the cytoplasm comprising D-psicose and / or D-tagatose as active ingredients.
- the gist of the present invention is a composition for preventing or treating the onset of a disease state associated with darcokinase activity described in any of (2) to (6) below.
- the present invention provides a composition for preventing or treating the onset of a disease state associated with darcokinase activity, which comprises D-psicose and / or D-tagatose as an active ingredient.
- the above thread composition is used for the prevention or treatment of pathological conditions related to darcokinase activity, which contains D-psicose and / or D-tagatose as an active ingredient.
- Food additives, food ingredients, foods and drinks, health foods and drinks, pharmaceuticals, and feed strength that can be selected
- the condition associated with the activity of dalcokinase is selected from impaired glucose tolerance, type 2 diabetes, hyperlipidemia, metabolic syndrome and obesity ability, or related to dalcokinase activity according to (2) or (3)
- a composition for preventing or treating the onset of a disease state is selected from impaired glucose tolerance, type 2 diabetes, hyperlipidemia, metabolic syndrome and obesity ability, or related to dalcokinase activity according to (2) or (3)
- a composition for preventing or treating the onset of a disease state is selected from impaired glucose tolerance, type 2 diabetes, hyperlipidemia, metabolic syndrome and obesity ability, or related to dalcokinase activity according to (2) or (3)
- a composition for preventing or treating the onset of a disease state is selected from impaired glucose tolerance, type 2 diabetes, hyperlipidemia, metabolic syndrome and obesity ability, or related to dalcokinase activity according to (2) or (3)
- a medicament which comprises D-psicose and / or D-tagatose together with one or more pharmaceutically acceptable carriers (3) or (4)
- a composition for the prevention or treatment of pathological conditions related to kinase activity is provided.
- the gist of the present invention is a food and drink with a label indicating that it is used for the prevention or treatment of pathological conditions related to the dalcokinase activity described in any of (7) to (11) below. To do.
- the food or drink according to (7) which is used for the prevention or treatment of pathological conditions related to darcokinase activity selected from impaired glucose tolerance, type 2 diabetes, hyperlipidemia, metabolic syndrome and obesity.
- the food or drink according to (7) or (8) which is a supplement, functional food, health food, food for specified health use, dietary supplement food or food for the sick.
- the effective amount of D-psicose and / or the amount of D-tagatose is 0.5 to 5 Og per day.
- the present invention treats a disease state related to darcokinase activity (prevention) simply by eating and drinking or oral administration in the form of food additives, food materials, food and drink, health food and drink, pharmaceuticals and feed. It is possible to provide a technique for using rare sugars D-psicose and / or D-tagatose that can be treated.
- FIG. 1 is a diagram illustrating darcokinase.
- FIG. 2 is a drawing for explaining the influence of D-fructose concentration on the rate of glucose phosphate in cultured hepatocytes.
- FIG. 3 is a drawing for explaining the mechanism of regulation of darcokinase activity by a darcokinase activity regulatory protein in hepatocytes.
- FIG. 4 is a drawing showing the results of examining the distribution of darcokinase in hepatocytes by a fluorescent antibody method using an anti-darcokinase antibody.
- FIG. 5 is a drawing explaining the mechanism of hepatic glucose metabolism due to translocation of darcokinase between the nucleus I cytoplasm and the disorder in type 2 diabetes.
- FIG. 6 shows changes in the distribution of dalcokinase in hepatocytes 30 minutes after loading after oral administration of D-glucose or D-fructose.
- FIG. 7 is a drawing illustrating the presence ratio of dalcokinase in the cytoplasm whose migration was promoted by low-concentration D-fructose.
- FIG. 8 shows changes in blood glucose levels in portal blood and peripheral blood after oral administration of D-glucose in type 2 diabetes model rats and healthy rats.
- FIG. 9 is a drawing explaining that when a small amount of D-fructose is administered to a rat type 2 diabetic patient, an increase in blood glucose level can be suppressed.
- FIG. 10 is a diagram showing the effect of D-ketose on the transfer of darcokinase to nuclear force cytoplasm.
- FIG. 11 is a diagram showing the effect of L-ketose on the transfer of Darcokinase to the nuclear force cytoplasm.
- FIG. 12 is a drawing showing the effect of D-ketose on lactic acid production.
- FIG. 13 A drawing illustrating the effect of D-psicose on the nuclear force cytoplasmic transition of darcokinase.
- FIG. 14 is a drawing showing the protocol of an experiment for confirming the transfer of Darcokinase to the nuclear force cytoplasm in animal experiments.
- FIG. 15 is a drawing showing a comparison of the results obtained by examining the intracellular distribution of darcokinase in the system of FIG. 14 by the fluorescent antibody method using an anti-darcokinase antibody.
- FIG. 16 is a drawing showing the protocol of an experiment for confirming the transfer of Darcokinase to the cytoplasm in animal experiments using a combination of D-glucose and D-psicose or D-fructose.
- FIG. 17 is a drawing showing a comparison of the results obtained by examining the distribution of darcokinase in hepatocytes by the fluorescent antibody method using an anti-darcokinase antibody in the system of FIG.
- FIG.18 Experimental protocol for investigating changes in the blood glucose level and insulin concentration in the tail vein and portal vein in the Goto-Kakizaki rat, a type 2 diabetes model animal, from the nucleus to the cytoplasm.
- FIG. 19 A drawing comparing the distribution of dalcokinase in the liver cells in the system of FIG. 18 by examining the distribution of nucleocytoplasm and cytoplasm of dalcokinase by the fluorescent antibody method using an anti-darcokinase antibody. is there.
- FIG. 20 is a drawing showing a comparison of cytoplasmic dalcokinase results obtained by analyzing the fluorescence image of FIG. 19.
- FIG. 21 is a drawing showing a comparison of blood glucose levels in the tail vein and portal vein in the system of FIG. 18.
- FIG. 22 is a drawing comparing the results of insulin concentration in the tail vein and portal vein in the system of FIG. 18. BEST MODE FOR CARRYING OUT THE INVENTION
- a compound that binds to the allosteric site of darcokinase and activates darcokinase is referred to as a “darcokinase activator”, a compound that promotes the transition of liver darcokinase between the nucleus and the cytoplasm.
- a “darcokinase activator” a compound that promotes the transition of liver darcokinase between the nucleus and the cytoplasm.
- promoters of the transition of darcokinase from nucleus to cytoplasm are called “promoters of the transition of darcokinase from nucleus to cytoplasm”.
- the above-mentioned “promoting agent for the transfer of darcokinase to nuclear force cytoplasm” causes an increase in the active darcokinase of inactive darcokinase, which is not limited to the transfer of darcokinase to the nuclear force cytoplasm. Also, ie, an active darcokinase increasing agent.
- cytoplasmic dalcokinase or nuclear force Darcokinase transferred to cytoplasm interacts with cytoplasmic proteins and organelles.
- darcokinase binds to fructose 2,6 bisphosphate synthase, which is involved in the regulation of glycolytic enzymes.
- darcokinase binds to other proteins to increase darcokinase activity. They suggest the possibility that darcokinase binds to mitochondria.
- dalcokinase binds to propiol CoA carboxylase present in mitochondria, the darcokinase activity increases. This is the force disclosed in Japanese Patent Laid-Open No. 2001-333778. If this effect is achieved with a rare sugar, do not experiment like this! /. In the present invention, this possibility is proved by an embodiment!
- Intracellular organelles or intracellular proteins interact with dalcokinase to change darcokinase activity, or the function of proteins interacting with intracellular organelles or dalcokinase changes.
- the above-mentioned “promoting agent of darcokinase nuclear power to the cytoplasm” is darcokina. It is defined to include an active darcokinase-increasing agent, ie, an active darcokinase-increasing agent, that causes an increase in inactive darcokinase, not limited to the transition to the cytoplasm.
- FIG. 1 is a diagram for explaining darcokinase.
- hexokinase is an enzyme that converts D-glucose into D-glucose 6-phosphate.
- There are four types of isozymes typel, typell, typeIII, typelV
- hexokinase typelV is dalcokinase.
- darcokinase has low affinity for glucose (Km; 5-10mM) and is not subject to feedback inhibition by D-glucose 6-phosphate. This enzyme is distributed in the splenic islets of Langeron, liver, brain, and intestinal tract.
- darcokinase plays an important role in homeostasis of blood glucose in the living body.
- Splenic Langerhans Islet ⁇ -cell Darcokinase has been demonstrated to be a glucose sensor that regulates insulin secretion by D-glucose stimulation.
- liver In the liver, it works to suppress the increase in blood glucose level after meals by promoting the use of sugar.
- Dalcokinase is also present in the nucleus of the hypothalamus, which is the center of the autonomic nervous system, and in the lining cells of the ventricular wall, so that this enzyme is also present in the brain parenchyma and cerebrospinal fluid. It is thought to function as a glucose sensor that senses
- FIG. 2 is a drawing for explaining the influence of D-fructose concentration on the rate of glucose phosphate in cultured hepatocytes.
- FIG. 3 is a drawing for explaining the mechanism of regulation of darcokinase activity by a darcokinase activity regulatory protein in hepatocytes.
- Figure 3 summarizes the mechanism of regulation of dalcokinase activity by the dalcokinase activity regulatory protein.
- a darcokinase activity regulatory protein binds to and inhibits the activity of darcokinase.
- the affinity between dalcokinase and dalcokinase activity-regulating protein is increased by D-fructose 6-phosphate and decreased by D-fructose 1-phosphate and high concentrations of glucose.
- darcokinase becomes inactive when bound to darcokinase activity-regulating protein, and becomes active when dissociated from darcokinase activity-regulating protein.
- D-glucose concentration outside the hepatocyte rises, the intracellular glucose concentration rises, the dalcokinase and the dalcokinase activity-regulating protein dissociate, and the darcokinase becomes inactive, and glucose phosphate becomes active. Increases, and D-glucose utilization increases.
- D-fructose is converted to D-fructose 1-phosphate by ketohexokinase.
- the resulting D-fructose 1-phosphate dissociates the dalcokinase and the dalcokinase activity regulating protein, and as with D-glucose, the darcokinase becomes an inactive form and becomes an active form of dalcoselin. Oxidation increases, and D-Dulcose use increases.
- FIG. 4 is a drawing showing the results of examining the distribution of dalcokinase in hepatocytes by a fluorescent antibody method using an anti-darcokinase antibody.
- the present inventors investigated the distribution of dalcokinase in hepatocytes by a fluorescent antibody method using an anti-darcokinase antibody, and found that darcokinase exists mainly in the cell nucleus. In addition, when D-glucose is orally administered to rats, darcokinase is transferred to the nuclear cytoplasm. Found out to do.
- Figure 4 shows primary cultured hepatocytes at 37 ° in the presence of 5 mM D-glucose, 25 mM D-glucose, 5 mM D-glucose + 0.5 mM D-fructose, or 25 mM D-glucose + 0.5 mM D-fructose.
- C incubated for 30 minutes, fixed hepatocytes with 4% paraformaldehyde, and examined the distribution of dalcokinase by the fluorescent antibody method. Green fluorescence indicates the distribution of darcokinase. At 5 mM D-glucose, gnorecokinase was mainly present in the cell nucleus.
- the distribution in hepatocytes was examined by the fluorescent antibody method using the anti-darcokinase activity regulating protein, and it was found that the darcokinase activity regulating protein was also present in the nucleus.
- FIG. 5 is a drawing for explaining the mechanism of liver glucose metabolism by translocation of darcokinase between the nucleus I cytoplasm.
- the present inventors proposed “the existence of a hepatic glucose metabolism mechanism by translocation of darcokinase between nucleus I and cytoplasm.” Subsequent research has ensured it. Regarding the mechanism of hepatic glucose metabolism by translocation between the nucleus I and cytoplasm of the nucleus, dalcokinase exists as an inactive form in combination with a darcokinase activity-regulating protein in the nucleus, in contrast to normal blood glucose levels.
- Darcokinase dissociates from the dalcokinase activity-regulating protein due to an increase in postprandial blood glucose or the presence of D-fructose, and then becomes active, moving to the nuclear cytoplasm to promote D-glucose metabolism, and then the blood glucose level is increased. When it decreases, it returns to the nucleus and binds to the darcokinase activity regulatory protein to become an inactive form (Fig. 5).
- FIG. 6 is a drawing showing changes in the distribution of darcokinase in liver cells after 30 minutes of loading with D-glucose! /, Administered orally with D-fructose.
- Goto-Kakizaki rats were orally administered to give 2 g glucose / kg body weight or 2 gD-darcose + 0.2 gD-fructose, and the distribution of dalcokinase in hepatocytes after 30 minutes of loading was examined. (Fig. 6) In Goto-Kakizaki rats, the transfer of darcokinase from the nucleus to the cytoplasm was incomplete. These results suggest that the failure of darcokinase to enter the nuclear cytoplasm may be associated with decreased hepatic glucose utilization and increased hepatic glucose production in patients with type 2 diabetes.
- Fig. 7 is a drawing for explaining the inhibitory action on glucose elevation by low concentration of D-fructose due to changes in the distribution of dalcokinase in hepatocytes.
- FIG. 8 is a drawing showing changes in blood glucose level after glucose loading.
- FIG. 9 is a diagram illustrating that an increase in blood glucose level can be suppressed by administration of a small amount of D-fructose.
- FIG. 10 is a drawing showing the effect of D-ketose in the transfer of darcokinase from the nucleus to the cytoplasm.
- Hepatocytes were incubated in MEM medium containing 5 mM or 15 mM glucose supplemented with D-ketose, and the translocation of darcokinase from the nucleus to the cytoplasm was examined. The results are shown in Fig. 10.
- glucokinase was transferred from the nucleus to the cytoplasm by the addition of D-fructose.
- D-fructose the addition of D-fructose to ImM or more gradually attenuated the transfer of darcokinase into the nuclear cytoplasm.
- D-psicose was added, darcokinase was transferred from the nucleus to the cytoplasm at any D-glucose concentration.
- D-tagatose was added to ImM
- dalcokinase also transferred nuclear power to the cytoplasm at any D-glucose concentration.
- the D-tagatose concentration was 10 mM or higher, the nuclear power of dalcokinase was not transferred to the cytoplasm.
- D-sorbose had little effect on dalcokinase translocation at any concentration.
- FIG. 11 is a drawing showing the effect of L-ketose on the transfer of darcokinase to the nuclear force cytoplasm.
- Liver cells were incubated in MEM medium containing 5 mM or 15 mM D-glucose supplemented with L-ketose, and the transfer of darcokinase to the nuclear cytoplasm was examined. The results are shown in FIG.
- FIG. 12 is a drawing showing the effect of D-ketose on lactic acid production.
- Hepatocytes were incubated in MEM medium containing 15 mM glucose supplemented with 5 mM or 20 mM D-ketose, and the time course of the amount of lactic acid in the MEM medium was examined.
- D as control
- FIG. 13 is a diagram illustrating the effect of D-psicose on the transition of darcokinase from the nucleus to the cytoplasm.
- D-psicose has the effect of promoting the transition of darcokinase from the nucleus to the cytoplasm. It can be expected to suppress the increase in blood sugar. The same is also possible with low concentrations of D-tagatose.
- Psicose is one of hexoses having a ketone group among monosaccharides. This psicose is known to have D and L isomers as optical isomers.
- D-psicose is a known substance but rarely exists in nature, so it is defined as “rare sugar” according to the definition of the International Society of Rare Sugars.
- D-psicose used in the present invention is a D-form of psicose classified as ketose and is a hexose (C H 0). Such a D-psi course
- D-psicose may be obtained by any means including those extracted from natural forces, those synthesized by chemical or biosynthesis methods, and the like.
- D-psicose is also produced by enzymatically producing D-fructose by epimerase, and may be completely purified, or may contain impurities contained in a small amount when enzymatically produced. That is, it is relatively easily prepared, for example, by a technique using epimerase (see, for example, JP-A No. 6-125776).
- the obtained D-psicose solution can be purified by methods such as deproteinization, decolorization, and desalting, if necessary, and concentrated to collect a syrup-like D-psicose product. 99% or more highly pure preparation can be easily obtained by fractionation and purification by chromatography.
- Such D-psicose can be used as a simple sugar.
- L-psicose is, for example, as described in JP-A-9-56390.
- sugar alcohol called aritol
- aritol can be produced as a raw material.
- the raw material, aritol can be easily obtained by the reduction reaction of D-psicose and can be used advantageously for the production of large amounts of L-psicose.
- L-psicose Bacteria used to produce L-psicose also have the ability to produce L-psicose, and belong to the genus Darconobacter.
- Gluconobacter flutula IF03254 or a mutant thereof can be advantageously used.
- these bacteria are cultured in a nutrient medium containing a carbon source such as glycerol, D-manntol, D-fructose, L-sorbose or xylitol, and preferably aerobic such as shaking or aeration agitation.
- L-psicose to be produced may be collected by culturing under conditions, converting aritol in the aqueous solution to L-psicose during culturing or using the obtained bacteria (viable cells).
- the obtained aqueous L-psicose solution can be purified by methods such as ammonium sulfate salting-out, deproteinization by zinc hydroxide adsorption, decolorization by activated carbon adsorption, and desalting by H-type or OH-type ion exchange resin.
- the syrupy L-psicose product can be collected by concentration. Further, a fraction having a purity of 99% or more can be easily obtained by fractionation, purification, and concentration by column chromatography using ion exchange resin.
- D-tagatose hydrolyzes ratatose or a ratatoose-containing substance into a mixture of D-galactose and D-glucose, optionally using ratase. It is produced by removing D-glucose and then chemical isomerization of D-galactose to D-tagatose.
- US Pat. No. 6057135 describes the production of D-tagatose from cheese whey or milk that is hydrolyzed to prepare a mixture of galactose and glucose. D-glucose is separated from D-galactose by fermentation of D-darcose and is subjected to isomerism using L-arabinose isomerase.
- D-psicose A compound obtained by converting the structure of a molecule from a certain starting compound by a chemical reaction is called a derivative of the starting compound.
- Derivatives of hexose containing D-psicose include sugar alcohols (when monosaccharides are reduced, aldehyde groups and keton groups become alcohol groups, resulting in the same number of polyhydric alcohols as carbon atoms), uronic acid ( It is an oxidized monosaccharide alcohol group, naturally known as D-glucuronic acid, galacturonic acid, and mannuronic acid), and amino sugar (substituted with NH group of OH group of sugar molecule).
- the present invention relates to a disease associated with dalcokinase activity, and the symptom is ameliorated or promoted by promoting the transfer of darcokinase to the nuclear cytoplasm, for example, impaired glucose tolerance,
- the present invention relates to food additives, food materials, food and drink, health food and drink, pharmaceuticals and feed that can be used for the prevention and treatment of type 2 diabetes, hyperlipidemia, metabolic syndrome, metabolic syndrome, obesity and the like.
- the composition targeted by the present invention is a food additive, food, health food, food for patient, food material, food material for health, food material for patient, food additive, food additive for health, food for patient Additives, beverages, health beverages, patient beverages, drinking water, health drinking water, patient drinking water, pharmaceuticals, pharmaceutical ingredients, feed, livestock and animal feed, D-psicose and / or It is characterized by containing as an active ingredient a yarn and composition containing D-tagatose.
- the present invention relates to an agent (formulation) for promoting the transfer of darcokinase from the nucleus to the cytoplasm, comprising D-psicose and / or D-tagatose as an active ingredient.
- D-psicoose and / or D-tagatose as an active ingredient is associated with a disease state associated with darcokinase activity (selected from glucose intolerance, type 2 diabetes, hyperlipidemia, metabolic syndrome and obesity) It relates to foods and drinks with indications that they are used for the prevention or treatment of pathological conditions. Accordingly, the preparation targeted for the present invention or the food for specified health use is characterized by containing the blended D-psicose and / or D-tagatose as an active ingredient.
- D-psicose and / or D-tagatose When D-psicose and / or D-tagatose is used as a preparation, it can be carried out by a known method. Specifically, for example, it can be carried out as described below.
- the preparation of the present invention comprises tablets, pills, and capsules that are sugar-coated or coated as necessary. It is preferably used orally as agents (including node capsules, soft capsules, microcapsules), powders, granules, fine granules, troches, liquids (including syrups, emulsions and suspensions).
- agents including node capsules, soft capsules, microcapsules
- powders including granules, fine granules, troches
- liquids including syrups, emulsions and suspensions.
- a physiologically acceptable carrier or the like can be blended as long as the effects of the present invention are not inhibited.
- physiologically acceptable carriers various organic or inorganic carrier substances commonly used as formulation materials are used. Excipients, binders, disintegrants, lubricants in solid formulations; solvents in liquid formulations, dissolution Auxiliaries, suspending agents, buffering agents, thickeners, emulsifiers and the like can be mentioned.
- preparation additives such as a coloring agent, a sweetening agent, and an anti-acid agent can be used as necessary.
- the preparation of the present invention may be coated.
- excipient examples include lactose, sucrose, D-mannitol, D-sorbitol, starch, pregelatinized starch, dextrin, crystalline cellulose (for example, microcrystalline cellulose), low-substituted hydroxypropylcellulose, and the like. , Sodium carboxymethyl cellulose, gum arabic gum, dextrin, pullulan, light caustic anhydride, synthetic aluminum silicate, magnesium magnesium metasilicate, and the like.
- binders include pregelatinized starch, sucrose, gelatin, macrogol, gum arabic, methylcellulose, carboxymethylcellulose, sodium carboxymethylcellulose, crystalline cellulose, sucrose, D-mann-tonole, trenorose, dextrin, punoreran. , Hydroxypropylcellulose (HPC), hydroxypropylmethylcellulose (HPMC), polybulurpyrrolidone (PVP) and the like.
- HPC Hydroxypropylcellulose
- HPMC hydroxypropylmethylcellulose
- PVP polybulurpyrrolidone
- Disintegrants include, for example, lactose, sucrose, starch, carboxymethylcellulose, carboxymethylcellulose calcium, cross-linked polybutylpyrrolidone, carmellose sodium, croscarmellose sodium, carboxymethylstarch sodium, light anhydrous key acid, low substituted hydroxy
- examples include propylcellulose, cation exchanged rosin, partially pregelatinized starch, and corn starch.
- the lubricant include stearic acid, magnesium stearate, calcium stearate, talc, waxes, colloidal silica, DL-leucine, sodium lauryl sulfate, magnesium lauryl sulfate, macrogol, and aerosil.
- Examples of the solvent include water for injection, physiological saline, Ringer's solution, alcohol, propylene.
- examples include render glycol, polyethylene glycol, medium chain fatty acid triglycerides (MCT), vegetable oils (eg safflower oil, sesame oil, corn oil, olive oil, cottonseed oil, soybean lecithin).
- solubilizers include polyethylene glycol, propylene glycol, D-mannitol, trehalose, benzyl benzoate, ethanol, trisaminomethane, cholesterol, triethanolamine, sodium carbonate, sodium citrate, sodium salicylate, Examples thereof include sodium acetate.
- suspending agent examples include surfactants such as stearyltriethanolamine, sodium lauryl sulfate, laurylaminopropionic acid, lecithin, benzalkonium chloride, benzethonium chloride, and glyceryl monostearate; Hydrophilic polymers such as alcohol, polybulyl pyrrolidone, carboxymethylenosulellose sodium, methinoresenorelose, hydroxymethinolesellose, hydroxyethylcellulose, hydroxypropylcellulose; polysorbates, polyoxyethylene hydrogenated castor oil, etc. can give.
- the buffer examples include buffer solutions of phosphate, acetate, carbonate, citrate, and the like.
- Examples of the thickener include natural gums and cellulose derivatives.
- Examples of the emulsifier include fatty acid esters (eg, sucrose fatty acid ester, glycerin fatty acid ester, sorbitan fatty acid ester, propylene glycol fatty acid ester), wax (eg, beeswax, rapeseed hydrogenated oil, safflower hydrogenated oil). , Palm hydrogenated oil, sitosterol, stigmasterol, campesterol, brush casterol, cacao butter powder, carnauba wax, rice wax, molasses, paraffin, etc.), lecithin (eg, egg yolk lecithin, soybean lecithin, etc.).
- fatty acid esters eg, sucrose fatty acid ester, glycerin fatty acid ester, sorbitan fatty acid ester, propylene glycol fatty acid ester
- wax eg, beeswax, rapeseed hydrogenated oil, s
- Examples of the colorant include water-soluble edible tar dyes (eg, edible dyes such as edible red Nos. 2 and 3, edible yellows Nos. 4 and 5, edible blue Nos. 1 and 2, and water-insoluble lakes).
- Examples include pigments (eg, aluminum salts of the above-mentioned water-soluble edible tar pigments), natural pigments (eg, j8-branch chin, chlorophyll, bengara, etc.)
- Sweeteners include, for example, sucrose, lactose, Examples include sodium saccharin, dipotassium glycyrrhizinate, aspartame, stevia, etc.
- Examples of the antioxidant include sulfite, ascorbic acid and their alkali metal salts, alkaline earth metal salts, and the like.
- coating may be performed by a usual method using a coating substrate.
- the coating base include sugar coating base, water-soluble film coating substrate, enteric film coating substrate and the like.
- sugar coating base examples include sucrose, and one or more kinds of talc, precipitated calcium carbonate, gelatin, gum arabic, pullulan, carnaparou and the like can also be selected.
- water-soluble film coating bases include, for example, senorelose such as hydroxypropylcellulose (HPC), hydroxypropylmethylcellulose (HPMC), ethylcellulose, hydroxy chineno resenorelose, and methino lesino xyeno resenorelose.
- senorelose such as hydroxypropylcellulose (HPC), hydroxypropylmethylcellulose (HPMC), ethylcellulose, hydroxy chineno resenorelose, and methino lesino xyeno resenorelose.
- Polymers Polyvinylacetal Jetylaminoacetate, Aminoalkyl Metaatalylate Copolymer E (Eudragit E (trade name), ROHM FALMA) Polyburylpyrrolidone, etc. Synthetic polymers; Polysaccharides such as pullulan .
- enteric film coating bases include cellulose polymers such as hydroxypropylmethylcellulose phthalate, hydroxypropylmethylcellulose acetate succinate, carboxymethylethylcellulose, and cellulose acetate phthalate; methacrylic acid copolymer L Acrylic acids such as Eudragit L (trade name) Rohm Falma), methacrylic acid copolymer LD (Eudragit L—30D 55 (trade name) Rohm Falma) methacrylic acid copolymer S (Eudragit S (trade name) Mouth Pharma) -Based polymers; natural products such as shellac. These coating bases may be coated singly or in combination of two or more at an appropriate ratio, or two or more may be sequentially coated.
- cellulose polymers such as hydroxypropylmethylcellulose phthalate, hydroxypropylmethylcellulose acetate succinate, carboxymethylethylcellulose, and cellulose acetate phthalate
- methacrylic acid copolymer L Acrylic acids such as Eudragit L (trade
- the food composition or food or drink of the present invention is a functional food, health food, It is preferably prepared as a functional food that may be prepared as a food for specified health use, a food for the sick, a supplement or the like.
- the shape of the food composition or food / beverage product of the present invention include tablets, rounds, capsules (including node capsules, soft capsules, and microcapsules), powders, granules, fine granules, and troches. And liquid (including syrup, milk, and suspension), and tablet-like and capsule-like are preferred.
- the food composition of the present invention is particularly preferably in the form of a tablet or a capsule.
- the food composition of the present invention can be produced, for example, by incorporating D-psicose and / or D-tagatose in the food by a known method.
- a tablet-like food yarn and composition includes, for example, D-psicose and / or D-tagatose, and excipients (for example, lactose, sucrose, mannitol, etc.), sweeteners, It can be produced by adding raw materials such as a flavoring agent, mixing them, and applying pressure with a tableting machine to form a tablet. If necessary, other ingredients (for example, vitamins such as vitamins, minerals such as iron, dietary fiber, etc.) can be added.
- the capsule-like food composition is, for example, filled with a liquid, suspension, paste, powder or granular food composition containing D-psicose and / or D-tagatose, or a capsule It can be manufactured by encapsulating with a base.
- a physiologically acceptable carrier for example, various conventional organic or inorganic carrier materials are used, and excipients, binders, disintegrants, lubricants, coloring agents, sweeteners, preservatives, antioxidants are used. , Thickeners and emulsifiers.
- food additives include coloring agents, sweetening agents, preservatives, antioxidants, and flavoring agents.
- other materials for example, minerals such as iron, dietary fibers such as pectin, carrageenan and mannan may be contained.
- Excipients binders, disintegrants, lubricants, solvents, solubilizers, suspending agents, buffers, thickeners, coloring agents, sweeteners, preservatives, antioxidants are Examples thereof are the same as those used in the preparation of the present invention described above.
- the vitamins may be water-soluble or fat-soluble, such as retinol palmitate, tocopherol, bisbenchamine, riboflavin, pyridoxine hydrochloride, cyanonoramine, sodium ascorbate, cholecalcifer. Rolls, nicotinic acid amide, calcium pantothenate, folic acid, piotin, choline bitartrate and the like.
- a coating substrate is used for the purpose of masking taste, improving light stability, improving appearance, or enteric properties. It may be coated by a method known per se. Examples of the coating substrate include those similar to those used in the above-mentioned preparation of the present invention, and can be carried out in the same manner.
- the composition of the present invention is in the form of a medicament and is associated with dalcokinase activity comprising D-psicose and / or D-tagatose together with one or more pharmaceutically acceptable carriers. It is a composition for prevention or treatment of pathological conditions.
- the pharmaceutical composition of the present invention is enteral, for example, oral or rectal, transdermal and non-human to mammals including humans, in order to promote and activate the translocation of dalcokinase to the cytoplasm. Suitable for enteral administration and for the treatment of conditions associated with dalcokinase activity. Examples of such medical conditions include impaired glucose tolerance, type 2 diabetes, hyperlipidemia, metabolic syndrome, metabolic syndrome, obesity and the like.
- the pharmaceutical composition comprises a therapeutically effective amount of a pharmacologically active compound of the invention, alone or in combination with one or more pharmaceutically acceptable carriers.
- the pharmacologically active compound of the present invention is used in the manufacture of a pharmaceutical composition comprising a therapeutically effective amount in association or mixing with an excipient or carrier suitable for enteral or parenteral administration.
- Diluents such as latatos, dextrose, sucrose, mannitol, sorbitol, cellulose and Z or glycine; lubricants such as silica, talcum, stearic acid, its magnesium or calcium salts and z or polyethylene renders Also for tablets, binders such as aluminum silicate magnesium, starch paste, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose and z or polyvinylpyrrolidone; optionally disintegrants such as starch, agar , Alginic acid or a sodium salt thereof; or an effervescent mixture; and
- compositions are preferably aqueous isotonic solutions or suspensions, and suppositories are advantageously prepared with fatty emulsions or suspensions.
- Such compositions are sterilized and may contain Z or adjuvants such as preservatives, stabilizers, wetting or emulsifying agents, solution promoters, osmotic salts and Z or buffering agents. Good. In addition, they may also contain other therapeutically valuable substances.
- the compositions are each prepared according to conventional mixing, granulating or coating methods and contain about 0.1-75%, preferably about 1-50%, of the active ingredient.
- Formulations suitable for transdermal applications include a therapeutically effective amount of a compound of the present invention with a carrier.
- a transdermal device is a backing member, a reservoir containing the compound, optionally with a carrier, and optionally the compound over a long period of time at a predetermined controlled rate to the host skin.
- the rate of delivery is in the form of a bandage including a control noria and means for securing the device to the skin.
- the pharmaceutical formulation is a therapeutically effective compound of the invention as defined above, either alone or in combination with another therapeutic agent, eg, in each therapeutically effective amount as reported in the art.
- Possible therapeutic agents include insulin, insulin derivatives or mimetics; insulin secretagogues; insulin secretion-enhancing sulfo-urea receptor ligands; PPAR ligands; insulin sensitizers; , GLP-1 analogs or mimetics; DPPIV inhibitors; HMG—CoA reductase inhibitors; squalene synthase inhibitors; FXR or LXR ligands; cholestyramine; fibrate; nicotinic acid or aspirin
- the invention relates to a pharmaceutical composition
- a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention in combination with one or more pharmaceutically acceptable carriers.
- the present invention is preferably selected from an antidiabetic agent, lipid lowering agent, antiobesity agent, antihypertensive agent or cardiotonic agent, most preferably from the antidiabetic agent or lipid lowering agent described above. It relates to a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention in combination with a therapeutically effective amount of another selected therapeutic agent.
- Disease conditions associated with dalcokinase activity more specifically impaired glucose tolerance, type 1 or type 2 diabetes, hyperlipidemia, metabolic syndrome, metabolic syndrome and obesity, preferably Relates to the use of a pharmaceutical composition or combination as described above for the manufacture of a medicament for the treatment of type 2 diabetes, impaired glucose tolerance and obesity.
- composition as described above for the treatment of conditions associated with dalcokinase activity preferably impaired glucose tolerance, type 1 or type 2 diabetes, hyperlipidemia, metabolic syndrome, metabolic syndrome and obesity About.
- a unit dose for a mammal of about 50-70 kg is about 1 mg to 20000 mg, advantageously about 5
- the therapeutically effective amount of the compound depends on the species of warm-blooded animal (mammal), the body weight, age, and individual condition, mode of administration and the compound involved.
- the compounds D-psicose and / or D-tagatose of the present invention are dalcokinase translocation promoters from the nucleus to the cytoplasm, and thus pathologies associated with glucocokinase activity as described herein, For example, impaired glucose tolerance, type 2 diabetes, hyperlipidemia
- the present invention provides the following.
- at least one other pharmaceutical composition comprising at least one other therapeutic agent (preferably selected from antidiabetic agents, lipid lowering agents, antiobesity agents, antihypertensive agents or cardiotonic agents).
- at least one other therapeutic agent preferably selected from antidiabetic agents, lipid lowering agents, antiobesity agents, antihypertensive agents or cardiotonic agents.
- therapeutic agents preferably selected from antidiabetic agents, lipid lowering agents, antiobesity agents, antihypertensive agents or cardiotonic agents.
- kits, parts for use in any of the above methods comprising a compound of formula I in free form or in the form of a pharmaceutically acceptable salt
- the kit may include instructions for its administration.
- a pharmaceutical composition of the invention (ii) an antidiabetic agent, an antiobesity agent, an antihypertensive agent, a cardiotonic agent or a lipid lowering agent, in the form of two separate units, components (i) and (ii) Or a pharmaceutically acceptable salt thereof.
- a kit of parts comprising a pharmaceutical composition comprising a selected compound.
- the compounds of the invention are administered to a mammal in need thereof.
- the compounds of the invention are used for the treatment of diseases that respond to the activity of dalcokinase activity.
- the pathology associated with dalcokinase activity is impaired glucose tolerance, type 2 diabetes, hyperlipidemia, metabolic syndrome and obesity, most preferably type 2 diabetes, impaired glucose tolerance. Selected from normal and obesity.
- a method or use of the invention comprising administration of said compound in combination with a therapeutically effective amount of an antidiabetic, antiobesity, antihypertensive, cardiotonic or lipid lowering agent.
- a method or use of the invention comprising administering said compound in the form of a pharmaceutical composition as described herein.
- treatment encompasses all various forms or modes of treatment known to those of skill in the art and is particularly prophylactic, Includes curative, delayed progression and palliative treatment.
- the above properties are advantageously demonstrated in in vitro and in vivo tests using mammals such as mice, rats, dogs, monkeys or isolated organs, tissues and preparations thereof.
- the compounds are applied in vitro in solution, for example preferably in the form of an aqueous solution, and enterally, parenterally, advantageously intravenously, eg in vivo as a suspension or aqueous solution. Can be done.
- the dosage in vitro may range from about 10_ 2 molar 10_ of 6 molar.
- In vivo therapeutically effective amounts may range from about 0.1 to 200 OOmgZkg, preferably ⁇ 1 to 5000mgZkg, depending on the route of administration.
- the liver is an important organ for maintaining blood glucose homeostasis.
- Darcokinase (EC 2.7.1.1), one of the rate-determining enzymes of glycolysis in liver glucose metabolism, exists as an inactive form in the nucleus when it binds to a darcokinase activity-regulating protein in the nucleus. Due to the increase in D-glucose concentration and the presence of low concentration of D-fructose, the dalcokinase regulatory protein dissociates and shifts to the cytoplasm from the nuclear force and promotes D-glucose metabolism. The translocation of darcokinase between the nucleus I and the cytoplasm is regulated by hormones. Insulin transfers darcokinase to the nuclear cytoplasm and glucagon to the cytoplasmic nucleus.
- Wistar rats male, 5-8 weeks old were used.
- Rat primary hepatocytes were incubated in MEM medium containing 25 mM D-glucose supplemented with hormones and various compounds for a certain period of time. Hepatocytes were fixed with 4% paraformaldehyde and stained by a fluorescent antibody method using an anti-darcokinase antibody. The fluorescence image acquired with the confocal laser microscope was analyzed with NIH Image to calculate the fluorescence intensity of the nucleus and cytoplasm, and the amount of darcokinase in the nucleus and cytoplasm was calculated.
- Rat primary cultured hepatocytes were incubated for a certain period of time in MEM medium containing 5 mM or 15 mM D-glucose supplemented with ketose. In the same manner as described above, the intracellular nuclear and cytoplasmic dalcokinase levels were determined.
- Cytoplasmic dalcokinase decreased.
- KT-5720 was allowed to act in the presence of glucagon, there was almost no decrease in cytoplasmic dalcokinase by glucagon. It is considered that the nuclear force of Darcokinase by insulin is transferred to the cytoplasm via PI3 kinase, and the transfer of Darcokinase by glucagon to the cytoplasmic force nucleus is via cAMP-dependent kinase. 2.Promoting translocation of darcokinase from nucleus to cytoplasm by glucose
- Ketose promotes the nuclear power of Darcokinase into the cytoplasm
- darcokinase was transferred from the nucleus to the cytoplasm in the presence of 5 mM or 15 mM D-glucose.
- D-tagatose was added at a concentration of 10 mM or more, there was no change in the migration of darcokinase.
- D-sorbose did not affect the migration of darcokinase at any concentration.
- D-psicose showed a facilitating action of darcokinase from the nucleus to the cytoplasm even at high concentrations. (Fig. 11)
- the nuclear power of Darcokinase by insulin is also transferred to the cytoplasm via PI3 kinase, and the transfer of Darcokinase from the cytoplasm to the nucleus by glucagon occurs via cAMP-A kinase.
- Psicose and low concentrations of tagatose cause the transfer of darcokinase from the nucleus to the cytoplasm.
- Figure 14 shows the protocol. -2g / kg for Wistar male rats fasted D-gnolecose, D-psicose, D-funoclectose, and a 1: 3 mixture of D-psicose and D-funoclectose were orally administered. Thirty minutes later, under anesthesia, the liver was removed immediately after fixation with 4% paraformaldehyde, and a frozen section was prepared. We analyzed the nuclear and cytoplasmic distribution of dalcokinase using a fluorescent antibody method using an anti-darcokinase antibody. At the same time, tail vein and portal force blood were collected and blood glucose levels were measured.
- Figure 16 shows the protocol. -Orally administer 2g / kg D-glucose to fasted Wistar male rats. Simultaneously, 0.2 g / kg D-psicose, D-fructose, and a 1: 3 mixture of D-psicose and D-fructose were orally administered. 30 minutes later under anesthesia In addition, after perfusion fixation with 4% baraformaldehyde, the liver was immediately removed and frozen sections were prepared. We analyzed the nuclear and cytoplasmic distribution of dalcokinase using a fluorescent antibody method using an anti-darcokinase antibody. At the same time, blood was collected from the tail vein and portal vein, and the blood glucose level was measured.
- Example 4 To investigate whether D-psicose has a pathologic improving effect in patients with type 2 diabetes, IGT (Impaired Glucose Tolerance), and patients with metabolic syndrome, It was orally administered to Goto-Kakizaki rats, a type 2 diabetes model animal, and liver darcokinase was transferred to the nuclear cytoplasm, and blood glucose and insulin concentrations in the tail vein and portal vein were measured.
- IGT Impaired Glucose Tolerance
- Figure 18 shows the protocol. -Orally administer 2g / kg D-glucose to fasted Goto-Kakizaki male rats. At the same time, 0.2 g / kg D-psicose was orally administered. After 30 and 60 minutes, under anesthesia, the liver was perfused and fixed with 4% paraformaldehyde, and the liver was removed and frozen sections were prepared. The nuclear and cytoplasmic distribution of hepatic dalcokinase was analyzed by a fluorescent antibody method using an anti-darcokinase antibody. At the same time, blood was collected from the tail vein and portal vein, and blood glucose and insulin concentrations were measured.
- the liver is divided into a portal vein region and a central vein region, and dalcokinase is known to be 1.3 times more potent and 1.5 times more active in the central vein region than the portal vein region.
- the nuclear and cytoplasmic distribution of dalcokinase in venous and portal vein regions was analyzed.
- Figure 19 shows the results of oral administration of D-glucose alone or D-glucose and D-psicose at the same time, and the distribution of dalcokinase by fluorescent antibody method in livers 30 and 60 minutes after administration. Show.
- Figure 20 shows the results of analyzing the fluorescence intensity of the nucleus and cytoplasm in the image of Figure 19.
- Figure 21 shows the results of changes in blood glucose levels in the tail vein and portal vein.
- the glucose concentration in the tail vein and portal vein at 30 and 60 minutes after simultaneous administration of D-psicose and D-glucose was significantly lower than that in the group administered with D-glucose alone. This result shows that D-psicose increases the active form of dalcokinase by translocation of dalcokinase into the nuclear cytoplasm, promotes hepatic glucose utilization, and suppresses the increase in blood glucose level.
- Figure 22 shows the results of changes in insulin concentration in the tail vein and portal vein due to glucose load.
- the insulin concentration in the tail vein and portal vein at 30 and 60 minutes after simultaneous administration of D-psicose and D-glucose was significantly lower than that in the group administered with D-glucose alone.
- This result suggests that D-psicose promotes hepatic glucose utilization and suppresses the increase in blood glucose level due to the transfer of dalcokinase from the nucleus to the cytoplasm, and suppresses insulin secretion such as splenic B cell strength. Show. Inhibition of insulin secretion is thought to conserve splenic B cells.
- D-psicose was found to be effective in patients with type 2 diabetes, IGT (Impaired Glucose Tolerance glucose intolerant, pre-diabetes group) patients, or patients with metabolic syndrome. It is thought to have an effect of improving the pathological condition. D-tagatose is considered to have the same effect as D-psicose.
- D-psicosose When D-psicosose is orally administered simultaneously to D-glucose in Goto-Kakizaki rats, a type 2 diabetes model animal, it shifts from the liver darcokinase nucleus to the cytoplasm and uses hepatic glucose more than D-glucose alone. Promotes to lower blood glucose levels and insulin levels.
- Darcokinase is not only for insulin secretion but also for insulin resistance under high fat diet. Compensation for spleen ⁇ 8 cell hyperplasia, because of the genetic predisposition to decrease insulin secretion, obesity by high-fat diet's obesity 'added insulin resistance, darcokinase or darcokinase activator Is an effective treatment method for type 2 diabetes because it promotes insulin secretion from spleen cells and also improves insulin secretion ability by increasing the amount of spleen
- D-psicose and D-tagatose are naturally occurring monosaccharides and are expected to have few side effects.
- D-fructose is said to have an effect of promoting the transition from the nucleus to the cytoplasm.
- D-fructose has energy, and excessive use of D-fructose is a problem.
- D-psicose and D-tagatose have the same effect of promoting the transition from the nucleus to the cytoplasm of dalcokinase, similar to D-fructose. Since the possibility of evil is low, it is considered useful.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Mycology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Fodder In General (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Saccharide Compounds (AREA)
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP07739883.2A EP2111865B1 (en) | 2006-11-17 | 2007-03-27 | Utilization of the function of rare sugar as promoter for the migration of glucokinase from nucleus to cytoplasm |
US12/515,321 US20100130435A1 (en) | 2006-11-17 | 2007-03-27 | Utilization of the function of rare sugar as promoter for the migration of glucokinase from nucleus to cytoplasm |
KR1020097010088A KR101373591B1 (ko) | 2006-11-17 | 2007-03-27 | 글루코키나아제의 핵으로부터 세포질로의 이행의 촉진화제로서, 희소당의 기능의 이용 |
JP2008544076A JP5633952B2 (ja) | 2006-11-17 | 2007-03-27 | D−プシコースを有効成分とするグルコキナーゼの核から細胞質への移行の促進剤 |
US14/339,582 US20140336267A1 (en) | 2006-11-17 | 2014-07-24 | Utilization of the function of rare sugar as promoter for the migration of glucokinase from nucleus to cytoplasm |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006310982 | 2006-11-17 | ||
JP2006-310982 | 2006-11-17 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/515,321 A-371-Of-International US20100130435A1 (en) | 2006-11-17 | 2007-03-27 | Utilization of the function of rare sugar as promoter for the migration of glucokinase from nucleus to cytoplasm |
US14/339,582 Division US20140336267A1 (en) | 2006-11-17 | 2014-07-24 | Utilization of the function of rare sugar as promoter for the migration of glucokinase from nucleus to cytoplasm |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2008059625A1 true WO2008059625A1 (en) | 2008-05-22 |
Family
ID=39401439
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2007/056445 WO2008059625A1 (en) | 2006-11-17 | 2007-03-27 | Utilization of the function of rare sugar as promoter for the migration of glucokinase from nucleus to cytoplasm |
Country Status (5)
Country | Link |
---|---|
US (2) | US20100130435A1 (ja) |
EP (1) | EP2111865B1 (ja) |
JP (1) | JP5633952B2 (ja) |
KR (1) | KR101373591B1 (ja) |
WO (1) | WO2008059625A1 (ja) |
Cited By (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009021740A2 (de) | 2007-08-15 | 2009-02-19 | Sanofis-Aventis | Substituierte tetrahydronaphthaline, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel |
JP2009286703A (ja) * | 2008-05-27 | 2009-12-10 | Matsutani Chem Ind Ltd | D−タガトースを有効成分とする体脂肪蓄積改善剤およびメタボリックシンドローム改善剤 |
JP2010018528A (ja) * | 2008-07-09 | 2010-01-28 | Matsutani Chem Ind Ltd | 食物繊維と希少糖を含む生体機能改善組成物。 |
WO2010054001A3 (en) * | 2008-11-04 | 2010-08-19 | University Of Kentucky Research Foundation | D-tagatose-based compositions and methods for preventing and treating atherosclerosis, metabolic syndrome, and symptoms thereof |
WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
WO2011157827A1 (de) | 2010-06-18 | 2011-12-22 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
WO2011161030A1 (de) | 2010-06-21 | 2011-12-29 | Sanofi | Heterocyclisch substituierte methoxyphenylderivate mit oxogruppe, verfahren zu ihrer herstellung und ihre verwendung als gpr40 rezeptor modulatoren |
WO2012004270A1 (de) | 2010-07-05 | 2012-01-12 | Sanofi | Spirocyclisch substituierte 1,3-propandioxidderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel |
WO2012004269A1 (de) | 2010-07-05 | 2012-01-12 | Sanofi | ( 2 -aryloxy -acetylamino) - phenyl - propionsäurederivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel |
WO2012010413A1 (de) | 2010-07-05 | 2012-01-26 | Sanofi | Aryloxy-alkylen-substituierte hydroxy-phenyl-hexinsäuren, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel |
WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
WO2013045413A1 (en) | 2011-09-27 | 2013-04-04 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
JP2014526258A (ja) * | 2011-09-15 | 2014-10-06 | シージェイ チェイルジェダング コーポレイション | 糖分解抑制性成分を含有する肥満予防及び改善用甘味素材組成物 |
WO2014175119A1 (ja) * | 2013-04-26 | 2014-10-30 | 松谷化学工業株式会社 | エネルギー消費の促進および/またはエネルギー消費機能低下の治療および/または予防剤、または方法 |
US9259022B2 (en) | 2013-03-15 | 2016-02-16 | Tate & Lyle Ingredients Americas Llc | Sweetener |
US9491960B2 (en) | 2013-03-15 | 2016-11-15 | Tate & Lyle Ingredients Americas Llc | Sweetener |
US9854827B2 (en) | 2013-03-15 | 2018-01-02 | Tate & Lyle Ingredients Americas Llc | Sweetener |
WO2021153718A1 (ja) * | 2020-01-31 | 2021-08-05 | 国立大学法人京都大学 | 線維芽細胞増殖因子21誘導剤、及びアルコール嗜好性又は単純糖質嗜好性を抑制するための組成物 |
CN117512033A (zh) * | 2023-12-21 | 2024-02-06 | 山东三元生物科技股份有限公司 | 一种由葡萄糖同时生产d-塔格糖和d-阿洛酮糖的方法 |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2156751B8 (en) * | 2007-05-18 | 2018-11-14 | Matsutani Chemical Industry Co., Ltd. | Novel sweetener having sugar-like taste and production method and use of the same |
JP6216493B2 (ja) * | 2011-06-24 | 2017-10-18 | 国立大学法人 香川大学 | 寿命延長剤 |
KR101486367B1 (ko) * | 2011-09-15 | 2015-01-26 | 씨제이제일제당 (주) | 지소화성 성분을 함유하는 당뇨 개선용 감미 소재 조성물 |
SG11201700445YA (en) | 2014-07-21 | 2017-02-27 | Roquette Freres | Sugar compositions for tableting by direct compression |
GB201602410D0 (en) | 2016-02-10 | 2016-03-23 | Tate & Lyle Ingredients | Methods for improving the gastrointestinal tolerance of food and beverage products comprising sweet, low-digestible carbohydrates |
KR101876534B1 (ko) * | 2016-09-02 | 2018-07-13 | 주식회사 삼양사 | 비알코올성 지방간 질환의 예방 또는 개선용 조성물 |
CN115715762A (zh) | 2016-12-15 | 2023-02-28 | 华领医药技术(上海)有限公司 | 葡萄糖激酶激活剂的口服制剂及其制备方法 |
EP3698648A1 (en) * | 2019-02-22 | 2020-08-26 | Pfeifer & Langen GmbH & Co. KG | Allulose pet food |
AU2022293501A1 (en) * | 2021-06-17 | 2024-01-18 | Ocean Spray Cranberries, Inc. | Rare sugars in food and beverage products |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0262887A (ja) * | 1988-05-05 | 1990-03-02 | Procter & Gamble Co:The | 低カロリーの機能性糖代替品 |
JPH0665080A (ja) * | 1992-03-10 | 1994-03-08 | Godo Shiyusei Kk | α−グルコシダ−ゼ阻害剤を含有する、過血糖付随疾患の予防・治療剤、および保健食 |
US5356879A (en) * | 1992-02-14 | 1994-10-18 | Biospherics, Incorporated | D-tagatose as anti-hyperglycemic agent |
WO2002058710A1 (en) * | 2001-01-25 | 2002-08-01 | University Of Maryland, Baltimore | Tagatose as a novel treatment for metabolic syndrome x, dyslipidemia, and coronary artery disease |
WO2003097820A1 (fr) * | 2002-05-22 | 2003-11-27 | Fushimi Pharmaceutical Co.,Ltd. | Procede pour utiliser l'activite physiologique d'un saccharide rare et compositions contenant un saccharide rare |
JP2005213227A (ja) * | 2004-01-30 | 2005-08-11 | Teikoku Seiyaku Co Ltd | D−プシコースの血糖上昇抑制効果の利用 |
WO2006101118A1 (ja) * | 2005-03-23 | 2006-09-28 | National University Corporation Kagawa University | D-プシコースの血糖値日内異常上昇抑制の用途 |
WO2007010975A1 (ja) * | 2005-07-20 | 2007-01-25 | Teikoku Seiyaku Co., Ltd. | D-プシコースの血中d-フラクトース濃度上昇抑制への使用 |
WO2007010976A1 (ja) * | 2005-07-20 | 2007-01-25 | Teikoku Seiyaku Co., Ltd. | D-プシコースを含有する体重増加抑制性組成物およびその利用方法 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5215251A (en) * | 1991-10-09 | 1993-06-01 | Beta Raven Inc. | Water controller |
-
2007
- 2007-03-27 WO PCT/JP2007/056445 patent/WO2008059625A1/ja active Application Filing
- 2007-03-27 EP EP07739883.2A patent/EP2111865B1/en active Active
- 2007-03-27 KR KR1020097010088A patent/KR101373591B1/ko active IP Right Grant
- 2007-03-27 US US12/515,321 patent/US20100130435A1/en not_active Abandoned
- 2007-03-27 JP JP2008544076A patent/JP5633952B2/ja active Active
-
2014
- 2014-07-24 US US14/339,582 patent/US20140336267A1/en not_active Abandoned
Patent Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0262887A (ja) * | 1988-05-05 | 1990-03-02 | Procter & Gamble Co:The | 低カロリーの機能性糖代替品 |
US5356879A (en) * | 1992-02-14 | 1994-10-18 | Biospherics, Incorporated | D-tagatose as anti-hyperglycemic agent |
US5447917A (en) * | 1992-02-14 | 1995-09-05 | Biospherics Incorporated | D-tagatose as anti-hyperglycemic agent |
JPH0665080A (ja) * | 1992-03-10 | 1994-03-08 | Godo Shiyusei Kk | α−グルコシダ−ゼ阻害剤を含有する、過血糖付随疾患の予防・治療剤、および保健食 |
WO2002058710A1 (en) * | 2001-01-25 | 2002-08-01 | University Of Maryland, Baltimore | Tagatose as a novel treatment for metabolic syndrome x, dyslipidemia, and coronary artery disease |
WO2003097820A1 (fr) * | 2002-05-22 | 2003-11-27 | Fushimi Pharmaceutical Co.,Ltd. | Procede pour utiliser l'activite physiologique d'un saccharide rare et compositions contenant un saccharide rare |
JP2005213227A (ja) * | 2004-01-30 | 2005-08-11 | Teikoku Seiyaku Co Ltd | D−プシコースの血糖上昇抑制効果の利用 |
WO2006101118A1 (ja) * | 2005-03-23 | 2006-09-28 | National University Corporation Kagawa University | D-プシコースの血糖値日内異常上昇抑制の用途 |
WO2007010975A1 (ja) * | 2005-07-20 | 2007-01-25 | Teikoku Seiyaku Co., Ltd. | D-プシコースの血中d-フラクトース濃度上昇抑制への使用 |
WO2007010976A1 (ja) * | 2005-07-20 | 2007-01-25 | Teikoku Seiyaku Co., Ltd. | D-プシコースを含有する体重増加抑制性組成物およびその利用方法 |
JP2007051137A (ja) * | 2005-07-20 | 2007-03-01 | Teikoku Seiyaku Co Ltd | D−プシコースを含有する体重増加抑制性組成物およびその利用方法 |
Non-Patent Citations (3)
Title |
---|
MATSUO T. ET AL.: "Effects of dietary D-psicose on diurnal variation in plasma glucose and insulin concentrations of rats", BIOSCIENCE, BIOTECHNOLOGY, AND BIOCHEMISTRY, vol. 70, no. 9, September 2006 (2006-09-01), pages 2081 - 2085, XP003022571 * |
MOORE M.C.: "Drug evaluation: tagatose in the treatment of type 2 diabetes and obesity", CURRENT OPINION IN INVESTIGATIONAL DRUGS, vol. 7, no. 10, October 2006 (2006-10-01), pages 924 - 935, XP003022570 * |
TOKUDA M.: "Iyaku to shite no Kishoto no Oyo (Application of rare sugars for medical purposes)", THE SOCIETY FOR BIOTECHNOLOGY TAIKAI KOEN YOSHISHU, 2005, pages 25, XP003022572 * |
Cited By (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009021740A2 (de) | 2007-08-15 | 2009-02-19 | Sanofis-Aventis | Substituierte tetrahydronaphthaline, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel |
JP2009286703A (ja) * | 2008-05-27 | 2009-12-10 | Matsutani Chem Ind Ltd | D−タガトースを有効成分とする体脂肪蓄積改善剤およびメタボリックシンドローム改善剤 |
JP2010018528A (ja) * | 2008-07-09 | 2010-01-28 | Matsutani Chem Ind Ltd | 食物繊維と希少糖を含む生体機能改善組成物。 |
JP2012506912A (ja) * | 2008-11-04 | 2012-03-22 | ユニバーシティ オブ ケンタッキー リサーチ ファウンデーション | アテローム硬化症、メタボリックシンドロームおよびそれらの症状を予防および処置するためのd−タガトースベースの組成物および方法 |
WO2010054001A3 (en) * | 2008-11-04 | 2010-08-19 | University Of Kentucky Research Foundation | D-tagatose-based compositions and methods for preventing and treating atherosclerosis, metabolic syndrome, and symptoms thereof |
US9060962B2 (en) | 2008-11-04 | 2015-06-23 | University Of Kentucky Research Foundation | D-tagatose-based compositions and methods for preventing and treating atherosclerosis, metabolic syndrome, and symptoms thereof |
RU2484827C2 (ru) * | 2008-11-04 | 2013-06-20 | Юниверсити Оф Кентукки Рисерч Фаундэйшн | Композиции на основе d-тагатозы и способы предупреждения и лечения атеросклероза, метаболического синдрома и их симптомов |
WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
WO2011157827A1 (de) | 2010-06-18 | 2011-12-22 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
WO2011161030A1 (de) | 2010-06-21 | 2011-12-29 | Sanofi | Heterocyclisch substituierte methoxyphenylderivate mit oxogruppe, verfahren zu ihrer herstellung und ihre verwendung als gpr40 rezeptor modulatoren |
WO2012010413A1 (de) | 2010-07-05 | 2012-01-26 | Sanofi | Aryloxy-alkylen-substituierte hydroxy-phenyl-hexinsäuren, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel |
WO2012004269A1 (de) | 2010-07-05 | 2012-01-12 | Sanofi | ( 2 -aryloxy -acetylamino) - phenyl - propionsäurederivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel |
WO2012004270A1 (de) | 2010-07-05 | 2012-01-12 | Sanofi | Spirocyclisch substituierte 1,3-propandioxidderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel |
WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
JP2016135122A (ja) * | 2011-09-15 | 2016-07-28 | シージェイ チェイルジェダング コーポレイション | 糖分解抑制性成分を含有する肥満予防及び改善用甘味素材組成物 |
JP2014526258A (ja) * | 2011-09-15 | 2014-10-06 | シージェイ チェイルジェダング コーポレイション | 糖分解抑制性成分を含有する肥満予防及び改善用甘味素材組成物 |
WO2013045413A1 (en) | 2011-09-27 | 2013-04-04 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
US9259022B2 (en) | 2013-03-15 | 2016-02-16 | Tate & Lyle Ingredients Americas Llc | Sweetener |
US9491960B2 (en) | 2013-03-15 | 2016-11-15 | Tate & Lyle Ingredients Americas Llc | Sweetener |
US9635879B2 (en) | 2013-03-15 | 2017-05-02 | Tate & Lyle Ingredients Americas Llc | Sweetener |
US9854827B2 (en) | 2013-03-15 | 2018-01-02 | Tate & Lyle Ingredients Americas Llc | Sweetener |
WO2014175119A1 (ja) * | 2013-04-26 | 2014-10-30 | 松谷化学工業株式会社 | エネルギー消費の促進および/またはエネルギー消費機能低下の治療および/または予防剤、または方法 |
JPWO2014175119A1 (ja) * | 2013-04-26 | 2017-02-23 | 松谷化学工業株式会社 | エネルギー消費の促進および/またはエネルギー消費機能低下の治療および/または予防剤、または方法 |
WO2021153718A1 (ja) * | 2020-01-31 | 2021-08-05 | 国立大学法人京都大学 | 線維芽細胞増殖因子21誘導剤、及びアルコール嗜好性又は単純糖質嗜好性を抑制するための組成物 |
CN117512033A (zh) * | 2023-12-21 | 2024-02-06 | 山东三元生物科技股份有限公司 | 一种由葡萄糖同时生产d-塔格糖和d-阿洛酮糖的方法 |
CN117512033B (zh) * | 2023-12-21 | 2024-04-19 | 山东三元生物科技股份有限公司 | 一种由葡萄糖同时生产d-塔格糖和d-阿洛酮糖的方法 |
Also Published As
Publication number | Publication date |
---|---|
EP2111865A4 (en) | 2010-08-04 |
US20140336267A1 (en) | 2014-11-13 |
JP5633952B2 (ja) | 2014-12-03 |
KR20090082403A (ko) | 2009-07-30 |
EP2111865B1 (en) | 2019-10-02 |
KR101373591B1 (ko) | 2014-03-12 |
EP2111865A1 (en) | 2009-10-28 |
US20100130435A1 (en) | 2010-05-27 |
JPWO2008059625A1 (ja) | 2010-02-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5633952B2 (ja) | D−プシコースを有効成分とするグルコキナーゼの核から細胞質への移行の促進剤 | |
US11219590B2 (en) | Anti-aging agent and anti-aging method | |
KR101809172B1 (ko) | 뮤신이 없는 배지에서 배양한 아커만시아 뮤시니필라 균주 또는 이의 배양액을 유효성분으로 함유하는 대사성 질환의 예방, 개선 또는 치료용 조성물 | |
US20220031596A1 (en) | Anti-aging agent and anti-aging method | |
WO2007053641A2 (en) | A-type procyanidins and inflammation | |
JP7461083B2 (ja) | ラクトバチルス属細菌由来小胞を含む代謝疾患又は筋肉疾患の予防又は治療用組成物 | |
JPH09176019A (ja) | 糖質分解消化酵素阻害剤並びにこれを配合した医薬品および飲食品 | |
CA2729622C (en) | Monoglyceride of acetoacetate and derivatives for the treatment of neurological disorders | |
EP3677273B1 (en) | Bacteroides cellulosityticus for use in preventing and/or treating atherosclerosis and obesity | |
EP3081097B1 (en) | Composition for the treatment of infertility | |
US8440619B2 (en) | Utilization of hypertension/hypercardia-preventing effect of D-allose | |
US20230117757A1 (en) | Coenzyme q production accelerator and method for accelerating coenzyme q production | |
EP3677272B1 (en) | Application of alistipes shahii in preparing a composition for preventing and/or treating lipid metabolism related diseases | |
KR20200060274A (ko) | 퇴행성 신경질환의 예방 또는 치료용 약학 조성물 | |
JPWO2008056452A1 (ja) | 希少糖の筋萎縮性側索硬化症と関連した運動障害の発症または進行の遅延への利用 | |
US9283243B2 (en) | CD36 inhibition to control obesity and insulin sensitivity | |
EP1951048A2 (en) | Flavanols and b-type procyanidins and inflammation | |
JP2022072837A (ja) | オキシトシン受容体作動性組成物 | |
JP4341891B2 (ja) | 血糖降下組成物 | |
WO2021153718A1 (ja) | 線維芽細胞増殖因子21誘導剤、及びアルコール嗜好性又は単純糖質嗜好性を抑制するための組成物 | |
JPH06504278A (ja) | ヒトの高い血糖値を低下させる方法 | |
WO2021006607A1 (ko) | Lgi3 유래 펩타이드를 유효성분으로 포함하는 당뇨병의 예방, 치료, 또는 개선용 조성물 | |
TW202131905A (zh) | Tgr5活化用組成物 | |
KR101751393B1 (ko) | 리놀레산 또는 이의 약학적으로 허용가능한 염을 유효성분으로 함유하는 근육손실 예방 및 치료용 약학적 조성물 | |
TW202346314A (zh) | 具有抗肥胖與抗糖尿病活性的胜肽、包含其之醫藥組成物及包含其之機能性食品組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07739883 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008544076 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020097010088 Country of ref document: KR |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007739883 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12515321 Country of ref document: US |